U.S. FDA approves TB Alliance's treatment for drug-resistant tuberculosis

The U.S. Food and Drug Administration has approved TB Alliance's treatment for drug-resistant tuberculosis as part of a three-drug combination regimen called BPaL, the not-for-profit said on Wednesday.